Related Experiment Videos
Ursodeoxycholic acid in primary biliary cirrhosis
1Department of Internal Medicine, University of Texas, Southwestern Medical Center at Dallas 75235, USA.
Seminars in Liver Disease
|May 1, 1997
Summary
Ursodeoxycholic acid (ursodiol) benefits primary biliary cirrhosis (PBC) patients by improving liver inflammation and disease progression markers. While safe and well-tolerated, its impact on survival and quality of life requires further study.
Area of Science:
- Hepatology
- Immunology
Background:
- Primary biliary cirrhosis (PBC) is a chronic liver disease.
- Cholestasis and hepatic inflammation are key features of PBC.
Purpose of the Study:
- To evaluate the efficacy of ursodeoxycholic acid (ursodiol) in managing PBC.
- To assess ursodiol's impact on laboratory markers, histology, and clinical outcomes in PBC patients.
Main Methods:
- Review of existing studies on ursodiol in PBC.
- Analysis of ursodiol's effects on liver function tests and histological features.
- Assessment of trends in liver transplantation and survival rates.
Main Results:
- Ursodiol improves cholestasis and inflammation markers.
- It also shows benefits in delaying histological progression in early PBC stages.
- Ursodiol is generally safe and well-tolerated.
Conclusions:
- Ursodiol offers significant benefits for PBC patients regarding biochemical and histological improvements.
- Further long-term, placebo-controlled trials are needed to confirm its effects on quality of life, liver transplantation rates, and survival.